New York University Grossman School of Medicine, Department of Pathology, 550 First Avenue, New York, NY 10016, United States.
MassGeneral Institute for Neurodegenerative Disease, Neurology, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States.
Neurobiol Dis. 2021 Jul;154:105344. doi: 10.1016/j.nbd.2021.105344. Epub 2021 Mar 22.
A variety of transgenic and knock-in mice that express mutant alleles of Amyloid precursor protein (APP) have been used to model the effects of amyloid-beta (Aβ) on circuit function in Alzheimer's disease (AD); however phenotypes described in these mice may be affected by expression of mutant APP or proteolytic cleavage products independent of Aβ. In addition, the effects of mutant APP expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of Aβ (Aβ42) associated with amyloid plaque accumulation in AD, though elevated concentrations of Aβ40, an Aβ species produced with normal synaptic activity, may also affect neural function.
To explore the effects of elevated expression of Aβ on synaptic function in vivo, we assessed visual system plasticity in transgenic mice that express and secrete Aβ throughout the brain in the absence of APP overexpression. Transgenic mice that express either Aβ40 or Aβ42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation.
Using two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female mice that express either 40- or 42-amino acid-long Aβ species demonstrate a plasticity defect comparable to that elicited in transgenic mice that express mutant alleles of APP and Presenilin 1 (APP/PS1 mice).
These data support the hypothesis that mutant APP-driven plasticity impairment in mouse models of AD is mediated by production and accumulation of Aβ. Moreover, these findings suggest that soluble species of Aβ are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of Aβ in both development and disease settings.
多种表达淀粉样前体蛋白(APP)突变等位基因的转基因和敲入小鼠已被用于模拟淀粉样β(Aβ)对阿尔茨海默病(AD)中回路功能的影响;然而,这些小鼠中描述的表型可能受到突变 APP 或蛋白水解切割产物的表达影响,而与 Aβ无关。此外,突变 APP 表达的影响归因于与 AD 中淀粉样斑块积累相关的淀粉样形成的、42 个氨基酸长的 Aβ(Aβ42)的表达升高,尽管正常突触活动产生的 Aβ40 浓度升高也可能影响神经功能。
为了在体内探索 Aβ表达升高对突触功能的影响,我们评估了在不过度表达 APP 的情况下在大脑中表达和分泌 Aβ的转基因小鼠的视觉系统可塑性。评估了表达 Aβ40 或 Aβ42 的转基因小鼠在单眼剥夺后适当表现出眼优势可塑性的能力。
使用两种互补方法来测量对单眼剥夺的可塑性反应,我们发现表达 40 或 42 个氨基酸长的 Aβ 物种的雄性和雌性小鼠表现出与表达 APP 和早老素 1(APP/PS1 小鼠)突变等位基因的转基因小鼠相似的可塑性缺陷。
这些数据支持这样的假设,即 AD 小鼠模型中突变 APP 驱动的可塑性损伤是由 Aβ的产生和积累介导的。此外,这些发现表明可溶性 Aβ 物种能够调节突触可塑性,可能与任何聚集无关。这些发现可能对可溶性 Aβ 物种在发育和疾病环境中的作用具有重要意义。